Dana–Farber Cancer Institute

Oncogenic Signaling Pathways in The Cancer Genome Atlas. (2018) Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, et al. Journal article A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk (2018) Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, Im HK, et al. Journal article Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing (2018) Shimelis H, Laduca H, Hu C, Hart SN, Na J, Thomas A, Akinhanmi M, et al. Journal article Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR (2018) Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, et al. Journal article Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018) Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al. Journal article The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma (2018) Fritchie K, Jensch K, Moskalev E, Caron A, Jenkins S, Link M, Brown PD, et al. Journal article Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period (2018) Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Warner RRP, et al. Conference contribution Integrated Safety Analysis of Telotristat Ethyl in Patients With Carcinoid Heart Disease (2018) Lapuerta P, Kulke MH, Pavel ME, Biran T, Fleming R, Zacks JS, Hoffmanns P, Warner RRP Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution